Skip to main content
. 2021 Jul 11;39(6):1604–1612. doi: 10.1007/s10637-021-01145-y

Table 4.

Best overall responsea per RECIST v1.0

Best response Dose escalation
(n = 25), n (%)
Dose expansion
(n = 18), n (%)
Overall response 0 0
 Complete response 0 0
 Partial response 0 0
Stable disease 6 (24) 7 (39)
Progressive disease 11 (44) 8 (44)

RECIST v1.0 Response Evaluation Criteria in Solid Tumours version 1.0

aTumor response assessments were not performed for all patients, only those that were reported are shown